CoChat

Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients

Morales, Leilani, Neven, Patrick, Timmerman, Dirk, Christiaens, Marie-Rose, Vergote, Ignace, Van Limbergen, Erik, Carbonez, An, Van Huffel, Sabine, Ameye, Lieveke, Paridaens, Robert · 2004 · Anti-Cancer Drugs
Cited by 144

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms. We analyzed the changes in frequency and severity of menopausal symptoms in patients receiving tamoxifen or aromatase inhibitors and identified factors influencing these symptoms. One hundred and eighty-one consecutive postmenopausal breast cancer patients scheduled to start endocrine treatment were included in this prospective study. A menopause symptom questionnaire covering vasomotor, atrophic, psychological, cognitive and somatic symptoms was filled in at baseline, and after 1 and 3 months of therapy. Both first-line tamoxifen and aromatase inhibitors induced an increase in the occurrence and severity of hot flashes (p<0.0001 and p=0.014, respectively). Musculoskeletal pain and dyspareunia significantly increased under first-line non-steroidal aromatase inhibitors (p=0.0039 and p=0.001, respectively), while patients under tamoxifen had significant decrease in sexual interest (p< or =0.0001). Younger age was associated with more hot flashes and vaginal dryness at baseline, and after 1 and 3 months of therapy (all p<0.02). We conclude that there are significant differences between the early effects of tamoxifen and aromatase inhibitors on menopausal symptoms of breast cancer patients. Our results underscore the need for safe and effective non-hormonal interventions to alleviate vasomotor and musculoskeletal symptoms which were the most prevalent and severe symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00001813-200409000-00003

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 144

Metadata

Authors
Morales, L., Neven, P., Timmerman, D., Christiaens, M.-R., Vergote, I., Van Limbergen, E., Carbonez, A., Van Huffel, S., Ameye, L., & Paridaens, R.
Venue
Anti-Cancer Drugs
Published
2004-09
Volume
15
Issue
8
Pages
753-760
ISSN
0959-4973 (ISSN-L)
OpenAlex
W2066447617
Cited by
144
References
2
FWCI
3.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. https://app.cochat.ai/papers/10.1097/00001813-200409000-00003
The paper
Morales, L., Neven, P., Timmerman, D., Christiaens, M.-R., Vergote, I., Van Limbergen, E., Carbonez, A., Van Huffel, S., Ameye, L., & Paridaens, R. (2004). Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-Cancer Drugs. https://doi.org/10.1097/00001813-200409000-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.